Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo treatment aims to boost stroke recovery

NCT ID NCT04667078

Disease control Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding a fast-acting blood thinner (cangrelor) to standard clot removal improves recovery in people with a severe stroke. About 368 adults with a large artery blockage in the brain will receive either cangrelor plus the procedure or the procedure alone. The main goal is to see if more patients have a good functional outcome (less disability) three months later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cangrelor (a blood thinner given by IV)
What this could lead to
If it works, this could improve recovery and reduce disability after a severe stroke.
What could go wrong
This is a Phase 3 trial, but results are not guaranteed. Adding a blood thinner may increase bleeding risk, and the benefit may be small or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 368 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2022

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 or older * Anterior circulation intracanial large artery occlusion isolated (Intracranial ICA and/or MCA) proved on CTA or MRA. * Symptoms onset \< 24h at imaging * Indication for MT and fulfillment of the following brain imaging criteria : 1. Perfusion imaging: An initial infarct volume (ischemic core on DWI or CTP calculated by the RAPID software) of less than 70 ml, a ratio between the critically hypoperfused lesion volume (calculated by RAPID with a TMax\>6s) and initial infarct volume of 1.8 or more, and an absolute difference between those 2 volumes of 15 ml or more. OR (if perfusion imaging not available or uninterpretable) : 2. CORE CLINICAL MISMATCH: Core calculated on DWI by RAPID, \<25 mL if NIHSS 6-20 and \<50 mL if NIHSS\>20 OR (if RAPID results are not considered reliable by the clinician) : 3. CORE CLINICAL MISMATCH according to the clinician evaluation * Pre-stroke mRS ≤ 2 * NIHSS ≥ 6 Exclusion Criteria: * Contraindication to MT * Patient over 80 years old with \>10 microbleeds on pre-treatment MRI * Pre-existing dependency with mRS ≥3. * Known tandem ICA-MCA occlusions requiring stenting * ASPECT\<6 on NCCT or DWI-MRI * Known hypersensitivity to cangrelor or to any of the excipients (mannitol, sorbitol) * History of previous intracranial hemorrhage * Evidence of active bleeding or acute trauma (fracture) on examination * Recent surgery with a significant risk of bleeding * VKA oral anticoagulation with INR \>1.7 * Curative heparin or direct oral anticoagulants (DOACs) in previous 48 hours with specific DOAC dosage ≥50 ng/ml and abnormal thrombin time for patients on dabigatran or abnormal specific anti-Xa activity for patients on apixaban, edoxaban, or rivaroxaban * Platelet count \<100 000/ mm3 * Woman of childbearing age without a pregnancy test or with a positive serum pregnancy test * Patient benefiting from a legal protection * Non-membership of a national insurance scheme * Opposition of the patient or (in case of inclusion as a matter of urgency) of the trustworthy person * Participation in another study regarding AIS care interfering with this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic disease ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    13 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU La Timone

    RECRUITING

    Marseille, 13005, France

  • CHU de Besançon

    RECRUITING

    Besançon, 25030, France

  • CHU de Strasbourg

    RECRUITING

    Strasbourg, 67200, France

  • Hospices civils de Lyon, Hôpital Pierre Wertheimer

    RECRUITING

    Bron, 69500, France

  • Hôpital Central (CHU de Nancy)

    RECRUITING

    Nancy, 54000, France

  • Hôpital Dupuytren (CHU Limoges)

    RECRUITING

    Limoges, 87000, France

  • Hôpital Foch

    RECRUITING

    Suresnes, 92150, France

  • Hôpital Fondation A de Rothschild

    RECRUITING

    Paris, 75019, France

  • Hôpital Lariboisière AP-HP

    RECRUITING

    Paris, 75010, France

  • Hôpital Pellegrin (CHU de Bordeaux)

    RECRUITING

    Bordeaux, France

  • Hôpital Pitié-Salpêtrière AP-HP

    RECRUITING

    Paris, 75013, France

  • Hôpital Purpan (CHU de Toulouse)

    RECRUITING

    Toulouse, 31300, France

  • Hôpital Salengro (CHU Lille)

    RECRUITING

    Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.